Dan-Feng Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dan-Feng Xu has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Chuanjie Zhang
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
40 shared publications - Hai Huang
Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
40 shared publications - Hanqing Liu
Division of Life Sciences and Medicine, Department of Urology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China
40 shared publications - Hongchao He
Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
40 shared publications - Jiawei Ding
Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
40 shared publications - Jun Xiao
Department of Urology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
40 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Assessment of pharmacological or toxicological effect of SKLB325 in treating PCa.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Assessment of pharmacological or toxicological effect of SKLB325 in treating PCa.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6/ATF4-sustained enhancer-promoter looping drives the transcription of glutathione biosynthesis pathway.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6/ATF4-sustained enhancer-promoter looping drives the transcription of glutathione biosynthesis pathway.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Identification of SPOP-JMJD6 regulating axis in PCa cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Identification of SPOP-JMJD6 regulating axis in PCa cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Characterization of JMJD6 clinical relevance in PCa samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Characterization of JMJD6 clinical relevance in PCa samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6-ATF4 complex regulates the ferroptosis susceptibility in PCa.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6-ATF4 complex regulates the ferroptosis susceptibility in PCa.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6 is important for SPOP-deficient PCa cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6 is important for SPOP-deficient PCa cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Oligonucleotides listed in this study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
Oligonucleotides listed in this study.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6 recruits Med1/14 to sustain enhancers activities.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from JMJD6 Rewires ATF4-Dependent Glutathione Metabolism to Confer Ferroptosis Resistance in SPOP-Mutated Prostate Cancer
JMJD6 recruits Med1/14 to sustain enhancers activities.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from BBOX1 Is a Metabolic Checkpoint That Mediates Metastatic Cancer Cell Evasion from Immunosurveillance by NK Cells
CXCR2-transduced NK cells display enhanced tumor infiltration.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from BBOX1 Is a Metabolic Checkpoint That Mediates Metastatic Cancer Cell Evasion from Immunosurveillance by NK Cells
CXCR2-transduced NK cells display enhanced tumor infiltration.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Video 5 from BBOX1 Is a Metabolic Checkpoint That Mediates Metastatic Cancer Cell Evasion from Immunosurveillance by NK Cells
Live imaging of coculture of RCC108-derived BBOX1neg cells (white border line) and Lifeact-GFP-expressing NK92 cells with or without slc22a5 knockdown (sislc22a5) when in the presence or absence of carnitine.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video 5 from BBOX1 Is a Metabolic Checkpoint That Mediates Metastatic Cancer Cell Evasion from Immunosurveillance by NK Cells
Live imaging of coculture of RCC108-derived BBOX1neg cells (white border line) and Lifeact-GFP-expressing NK92 cells with or without slc22a5 knockdown (sislc22a5) when in the presence or absence of carnitine.